Research and Markets: Eli Lilly Executive Report - a Publicly Traded Global Pharmaceutical Company Based in Indiana, US

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/e4d3f4/eli_lilly_executiv) has announced the addition of the "Eli Lilly Executive Report" company profile to their offering.

Eli Lilly and Company is a publicly traded global pharmaceutical company based in Indiana, US. Founded in 1876, Eli Lilly was the first company to mass-produce penicillin and today is the world's largest manufacturer and distributor of psychiatric medications. With approximately 40,000 employees worldwide and products marketed in 143 countries, it is currently the 10th largest pharmaceutical company in the world measured by revenues.

Operating in one significant business segment human pharmaceutical products most of the Company's revenue comes from the sale of medicines in the therapeutic areas of neuroscience, endocrinology, oncology and cardiovascular, with top-selling products including: Zyprexa, Cymbalta, Humalo, Alimta, Cialis and Prozac.

In 2009, Eli Lily reported revenues of $21.8bn and an operating profit of $6.4bn. $4.3bn was invested in R&D.

This Latin Brains Executive Report offers a thorough yet concise strategic analysis of Eli Lilly's global business. The report provides clear insight into: the way the company's business is organized; its portfolio of products; its recent and most significant developments in R&D; its financial situation; its growth strategy and relevant corporate news. All of this is taken into consideration to examine and understand the strengths and weaknesses derived from the company's current situation, as well as the opportunities and threats arising from issues that affect the pharmaceutical industry as a whole.

Whether using it as a first-time approach to understand your clients business or as a way to get the full picture of your competitors current situation and its prospects, this report is the solution. While providing all the relevant information you need to acquire fully comprehensive knowledge of the company you are researching, it is presented in a clear and systematic way. The research has already been done for you: we understand time is of the essence and we aim to make sure you can make the best use of it, without having to browse through pointless facts and figures when we can make all the important information readily available for you.

This report includes:

  • A detailed overview of the company's staple marketed products, as well as of its newest and most innovative developments being currently launched or in late-stage trials;
  • Comprehensive analysis of the strategy which drives the company's business model and of the financial results obtained;
  • Significant events regarding the company's operations: M&A activity, legal issues, collaboration deals and executive appointments;
  • Key information on the company's geographic distribution;
  • SWOT analysis examining opportunities for growth and risk factors.

Key Topics Covered:

Company overview & Business units

Location

Financials

Outlook

Recent events: M&A activity, pipeline snapshot, product launches, product approvals, appointments, new operating model.

Strategy

SWOT analysis

Key people

Additional reading

Products Mentioned:

  • Zyprexa
  • Cymbalta
  • Humalog
  • Alimta
  • Cialis
  • Prozac
  • Strattera
  • Humulin
  • Evista
  • Gemzar
  • Erbitux
  • Effient
  • Xigris
  • Rumensin
  • Tylan
  • Posilac
  • Vancocin HCl
  • Ceclor
  • Byetta
  • Forteo
  • Livalo

For more information visit http://www.researchandmarkets.com/research/e4d3f4/eli_lilly_executiv



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America

INDUSTRY KEYWORDS:   Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.